-+ 0.00%
-+ 0.00%
-+ 0.00%

BeOne Medicines publishes 2025 annual report

PUBT·04/14/2026 12:54:48
Listen to the news
BeOne Medicines publishes 2025 annual report
  • BeOne Medicines published its 2025 annual report, highlighting a shift to sustained profitability with positive operating and free cash flow.
  • BRUKINSA extended global reach, holding market leadership across B-cell malignancies in 2025 with approvals in more than 75 markets.
  • Sonrotoclax secured first global regulatory clearance in China in December 2025, positioning it as a new foundational option in B-cell cancers.
  • BGB-16673 advanced into late-stage development with a Phase 3 head-to-head trial versus pirtobrutinib, targeting patients with BTK-inhibitor resistance.
  • Company reiterated strategic emphasis on an in-house global clinical development model, aiming to shorten timelines and lower trial costs versus CRO-heavy peers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeOne Medicines AG published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260414-12105497), on April 14, 2026, and is solely responsible for the information contained therein.